GP1BA

Summary

GP1BA (glycoprotein Ib platelet subunit alpha, HGNC:4439) is a protein-coding gene on chromosome 17p13.2, encoding Platelet glycoprotein Ib alpha chain (P07359). GP-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of vWF, which is already bound to the subendothelium.

Glycoprotein Ib (GP Ib) is a platelet surface membrane glycoprotein composed of a heterodimer, an alpha chain and a beta chain, that is linked by disulfide bonds. The Gp Ib functions as a receptor for von Willebrand factor (VWF). The complete receptor complex includes noncovalent association of the alpha and beta subunits with platelet glycoprotein IX and platelet glycoprotein V. The binding of the GP Ib-IX-V complex to VWF facilitates initial platelet adhesion to vascular subendothelium after vascular injury, and also initiates signaling events within the platelet that lead to enhanced platelet activation, thrombosis, and hemostasis. This gene encodes the alpha subunit. Mutations in this gene result in Bernard-Soulier syndromes and platelet-type von Willebrand disease. The coding region of this gene is known to contain a polymophic variable number tandem repeat (VNTR) domain that is associated with susceptibility to nonarteritic anterior ischemic optic neuropathy.

Source: NCBI Gene 2811 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Bernard-Soulier syndrome (Definitive, ClinGen) — +3 more curated relationships
• GWAS associations: 17
• Clinical variants (ClinVar): 337 total — 20 pathogenic, 68 likely-pathogenic
• Phenotypes (HPO): 50
• Druggable target: yes
• MANE Select transcript: NM_000173

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4439
Approved symbol	GP1BA
Name	glycoprotein Ib platelet subunit alpha
Location	17p13.2
Locus type	gene with protein product
Status	Approved
Aliases	HPA-2, CD42b, GPIbalpha
Ensembl gene	ENSG00000185245
Ensembl biotype	protein_coding
OMIM	606672
Entrez	2811

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000329125

RefSeq mRNA: 1 — MANE Select: NM_000173 NM_000173

CCDS: CCDS54068

Canonical transcript exons

ENST00000329125 — 2 exons

Exon	Start	End
ENSE00001645621	4932277	4932365
ENSE00002252699	4932599	4935023

Expression profiles

Bgee: expression breadth ubiquitous, 186 present calls, max score 86.47.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 2.0235 / max 395.5119, expressed in 147 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
158963	1.5350	134
158964	0.2319	55
158962	0.2088	54
158961	0.0479	12

Top tissues by expression

274 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	86.47	gold quality
mononuclear cell	CL:0000842	86.10	gold quality
leukocyte	CL:0000738	85.49	gold quality
lymph node	UBERON:0000029	82.16	gold quality
buccal mucosa cell	CL:0002336	78.59	silver quality
secondary oocyte	CL:0000655	76.24	gold quality
pancreatic ductal cell	CL:0002079	75.96	silver quality
cervix squamous epithelium	UBERON:0006922	75.62	silver quality
trabecular bone tissue	UBERON:0002483	75.28	silver quality
tongue squamous epithelium	UBERON:0006919	75.24	gold quality
diaphragm	UBERON:0001103	74.65	gold quality
granulocyte	CL:0000094	74.36	gold quality
oocyte	CL:0000023	73.27	gold quality
blood	UBERON:0000178	73.10	gold quality
bone marrow cell	CL:0002092	72.80	silver quality
olfactory bulb	UBERON:0002264	72.64	gold quality
ileal mucosa	UBERON:0000331	72.53	gold quality
tibialis anterior	UBERON:0001385	72.22	silver quality
type B pancreatic cell	CL:0000169	71.96	gold quality
bone marrow	UBERON:0002371	71.27	gold quality
endothelial cell	CL:0000115	70.80	gold quality
vermiform appendix	UBERON:0001154	70.36	gold quality
caecum	UBERON:0001153	69.89	gold quality
tonsil	UBERON:0002372	69.76	gold quality
periodontal ligament	UBERON:0008266	69.50	gold quality
hair follicle	UBERON:0002073	68.16	gold quality
cranial nerve II	UBERON:0000941	68.09	gold quality
epithelial cell of pancreas	CL:0000083	67.45	gold quality
quadriceps femoris	UBERON:0001377	67.25	gold quality
vastus lateralis	UBERON:0001379	67.08	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-9388	yes	359.41
E-CURD-112	yes	35.07
E-HCAD-10	yes	17.61
E-ANND-3	no	2.15

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ETV6, FLI1, GATA1, RUNX1, ZBTB16

miRNA regulators (miRDB)

36 targeting GP1BA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-7844-5P	99.55	68.56	1428
HSA-MIR-4762-3P	99.43	69.72	2363
HSA-MIR-942-5P	99.41	68.40	1977
HSA-MIR-3182	99.40	68.15	2454
HSA-MIR-4999-5P	99.35	69.15	926
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-4727-5P	99.23	67.55	1154
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-3199	99.17	65.19	696
HSA-MIR-8052	99.17	65.01	719
HSA-MIR-6738-3P	99.03	67.14	1326
HSA-MIR-3611	98.76	68.76	1290
HSA-MIR-6811-3P	98.62	66.54	944

Literature-anchored findings (GeneRIF, showing 40)

• The von Willebrand factor- and thrombin-binding activities of recombinant GPIb alpha(1-289) expressed in a baculovirus/insect cell system are identical to those of an equivalent fragment derived from human platelets. (PMID:11437595)
• Two compound heterozygotes for the GPIbalpha gene(a maternal T insertion at position 1418 causing a translational frameshift and premature polypeptide termination, and a paternal T715A substitution changing Cys209 to Ser)had Bernard-Soulier syndrome. (PMID:11776304)
• GP Ibalpha initiates ERK activation, and regulates ERK-induced EC migration on vWF. (PMID:11776327)
• Molecular models of the 7 Leu-rich repeats of human GPIb alpha, illustrate the species-specific interaction between human vWF and its receptor. A large negatively charged patch exists on the concave face of repeats 2-4. (PMID:11858495)
• Platelet glycoprotein Ib function and reactivity of platelets was studied in diabetic and non-diabetic hemodialysed pts. GP1B level and function was decreased only in non-DM pts. (PMID:11858499)
• The Kozak sequence polymorphism of the glycoprotein Ib alpha gene had no impact on the risk of coronary heart disease, its effect on extent of CHD remains to be seen. (PMID:11859854)
• Absence of GPIbalpha is responsible for aberrant membrane development during megakaryocyte maturation; leads to abnormal partitioning of the membrane systems and abnormal proplatelet production. (PMID:11937271)
• Site-directed mutagenesis demonstrates residues involved in the sulfation of tyrosines 276, 278, and 279 and residues crucial for botrocetin-mediated VWF binding. (PMID:12036871)
• Hypercholesterolemia primes platelets for recruitment via VWF, GPIb alpha, and P-selectin to lesion-prone sites, before lesions are detectable. Platelet tethering to vascular endothelium was mainly mediated by platelet GPIb alpha (PMID:12036879)
• the rGPIa/IIa-collagen interaction dominates the adhesion of rGPIa/IIa-Ib alpha-liposomes to the collagen surface at low shear rates; the rGPIa/IIa-collagen and rGPIb alpha-VWF interactions synergistically support liposome adhesion at high shear rates. (PMID:12070018)
• crystal structure of N-terminal domain reveals an unmasking mechanism for receptor activation (PMID:12087105)
• Ligand binding of GPIb, without receptor clustering, is sufficient to activate Src. (PMID:12393736)
• structure-activity relationship of mutations found in Bernard-Soulier syndrome (PMID:12463594)
• The polymorphisms affecting the structure or level of the main adhesive platelet glycoproteins (GPs) plays a minor role in genetic risk factors for arterial thrombotic disorders. (PMID:12499711)
• A role of the GPIb alpha intracellular domain was shown. VWF-dependent adhesion of cells containing deletions of the entire (Delta 518-610) or portions (Delta 535-568, Delta 569-610) of the GPIb alpha cytoplasmic tail was insensitive to RAM.1 inhibition. (PMID:12522011)
• The cytoplasmic domain of GPIb alpha is important in the GPIb-IX-von Willebrand factor interaction under both static and flow conditions, modulating the strength of the bond between receptor and ligand. (PMID:12590614)
• analysis of kinetic and mechanical properties of tether bonds formed between patient VWD platelets and the A1-domain of VWF indicate that GPIba mutation, Gly233Val, promotes and stabilizes platelet adhesion to VWF (PMID:12637314)
• binding of thrombin to GPIbalpha induces fibrin binding to resting alphaIIbbeta3 leading to fibrin-dependent platelet aggregation and clot retraction, that can be selectively inhibited by alphaIIbbeta3 antagonists (PMID:12719784)
• shear-dependent VWF-induced platelet activation affects filamin A binding to GpIb-IX-V, and filamin A binding to the cytoplasmic tail of GpIbalpha regulates proaggregatory tyrosine kinase signaling. (PMID:12791664)
• determined the structure of platelet glycoprotein Ibalpha (GpIbalpha) bound to thrombin at 2.3 angstrom resolution and defined two sites in GpIbalpha that bind to exosite II and exosite I of two distinct alpha-thrombin molecules, respectively (PMID:12855810)
• crystal structure of the GpIbalpha-thrombin complex at 2.6 angstrom resolution reveals simultaneous interactions of GpIbalpha with exosite I of one thrombin molecule, and with exosite II of a second thrombin molecule (PMID:12855811)
• in human platelets, GPIbalpha and ADP act in synergy to amplify PAR1 coupled responses while PAR4 is activated independently of GPIbalpha and ADP. (PMID:12871418)
• Convulxin binds weakly to murine platelet GPIb alpha but more strongly to human platelet GPIb alpha (PMID:12881531)
• Mac-1 and glycoprotein Ib bind in an interaction mediated by high molecular weight kininogen (PMID:12952972)
• GPIb translocation is powered by a contractile mechanism involving Ca2+ mobilization, actin polymerization, and myosin incorporation into the cytoskeleton and both PAR-1 and PAR-4 can activate this process (PMID:14521606)
• association between the presence of different VNTR alleles of GP Ibalpha and the frequency of coronary heart disease (PMID:14592833)
• The presence of the VNTR B allele of glycoprotein Ibalpha confers a significant risk for NAION (nonarteritic anterior ischemic optic neuropathy) (PMID:14711733)
• binding of thrombin to GPIbalpha induced an intracellular signaling leading to the interaction of the platelet integrin alphaIIbbeta3 with the fibrin-dodecapeptide sequence of the gamma chain (PMID:14961148)
• in the absence of GPIbalpha or following inhibition of thrombin binding to GPIbalpha, there is a reduction in the thrombin-induced calcium flux, beta3 cleavage and micro -calpain activation. (PMID:15045135)
• existence of a second major 14-3-3zeta binding site within the cytoplasmic tail of GPIbalpha that has an important functional role in regulating integrin-dependent cell spreading. (PMID:15054037)
• Results suggest that von Willebrand factor domain A1 inhibits the cleavage of domain A2 by ADAMTS13, and that inhibition can be relieved by interaction of domain A1 with platelet platelet glycoprotein Ibalpha or certain glycosaminoglycans. (PMID:15249683)
• VNTR of the GPIba gene may have a role in development of myocardial infarction (PMID:15269835)
• The homozygous glycoprotein 1b alpha (-5)T/C Kozak polymorphism increases the risk of ischemic cerebrovascular events 3.5 fold, consistent with its reported gene dose effect on GP 1b alpha/IX/V receptor density on platelets. (PMID:15311155)
• binding of FXI to GPIbalpha is mediated by amino acids in the A3 domain in the presence or absence of HK. (PMID:15317813)
• AP1 protein binds to specific region, which facilitates binding to Von Willebrand factor. (PMID:15319289)
• FXI binds to glycoprotein Ibalpha at sites comprising the leucine-rich repeat sequences within the NH2-terminal globular domain that are separate and distinct from the thrombin-binding site (PMID:15375170)
• Streptoccus gordonii Gspb and Hsa mediate streptococcal adherence to sialylated platelet membrane glycoprotein Ibalpha (PMID:15501784)
• the association involves an interaction between the ectodomains of GPIb alpha and GPVI (PMID:15841318)
• a gain-of-function phenotype resulting from mutations in the LRR region of GP Ibalpha; data suggest that the LRRs regulate GP Ibalpha affinity for VWF allosterically (PMID:15933060)
• analysis of platelet glycoprotein I(b)alpha and integrin alpha2beta1 polymorphisms in diverse populations (PMID:15978109)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Gp1ba	ENSMUSG00000050675
rattus_norvegicus	Gp1ba	ENSRNOG00000025959

Paralogs (22): DCN (ENSG00000011465), RTN4R (ENSG00000040608), ASPN (ENSG00000106819), FLRT3 (ENSG00000125848), FLRT1 (ENSG00000126500), LRRC4 (ENSG00000128594), LRRC4B (ENSG00000131409), PODNL1 (ENSG00000132000), LRTM1 (ENSG00000144771), LRRC4C (ENSG00000148948), LRRTM1 (ENSG00000162951), LRRC15 (ENSG00000172061), PODN (ENSG00000174348), LRRTM4 (ENSG00000176204), BGN (ENSG00000182492), LRRC19 (ENSG00000184434), FLRT2 (ENSG00000185070), RTN4RL1 (ENSG00000185924), RTN4RL2 (ENSG00000186907), NYX (ENSG00000188937), LRRC66 (ENSG00000188993), LRRTM3 (ENSG00000198739)

Protein

Protein identifiers

Platelet glycoprotein Ib alpha chain — P07359 (reviewed: P07359)

Alternative names: Antigen CD42b-alpha

All UniProt accessions (1): P07359

UniProt curated annotations — full annotation on UniProt →

Function. GP-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of vWF, which is already bound to the subendothelium.

Subunit / interactions. Two GP-Ib beta are disulfide-linked to one GP-Ib alpha. GP-IX is complexed with the GP-Ib heterodimer via a non covalent linkage. Interacts with FLNB. Interacts with FLNA (via filamin repeats 4, 9, 12, 17, 19, 21, and 23). (Microbial infection) Interacts with Staphylococcus aureus protein SSL5.

Subcellular location. Membrane.

Post-translational modifications. Glycocalicin is the product of a proteolytic cleavage/shedding, catalyzed by ADAM17, which releases most of the extracellular domain. Binding sites for vWF and thrombin are in this part of the protein.

Disease relevance. Non-arteritic anterior ischemic optic neuropathy (NAION) [MIM:258660] An autosomal recessive ocular disease due to ischemic injury to the optic nerve. It usually affects the optic disk and leads to visual loss and optic disk swelling of a pallid nature. Visual loss is usually sudden, or over a few days at most and is usually permanent, with some recovery possibly occurring within the first weeks or months. Patients with small disks having smaller or non-existent cups have an anatomical predisposition for non-arteritic anterior ischemic optic neuropathy. As an ischemic episode evolves, the swelling compromises circulation, with a spiral of ischemia resulting in further neuronal damage. Disease susceptibility is associated with variants affecting the gene represented in this entry. Bernard-Soulier syndrome (BSS) [MIM:231200] An autosomal recessive coagulation disorder characterized by a prolonged bleeding time, unusually large platelets, thrombocytopenia, and impaired prothrombin consumption. The disease is caused by variants affecting the gene represented in this entry. Bernard-Soulier syndrome A2, autosomal dominant (BSSA2) [MIM:153670] A coagulation disorder characterized by mild to moderate bleeding tendency, thrombocytopenia, and an increased mean platelet volume. Some individuals have no symptoms. Mild bleeding tendencies manifest as epistaxis, gingival bleeding, menorrhagia, easy bruising, or prolonged bleeding after dental surgery. The disease is caused by variants affecting the gene represented in this entry. von Willebrand disease, platelet-type (VWDP) [MIM:177820] An autosomal dominant bleeding disorder characterized by abnormally enhanced binding of von Willebrand factor by the platelet glycoprotein Ib (GP Ib) receptor complex. Hemostatic function is impaired due to the removal of VWF multimers from the circulation. The disease is caused by variants affecting the gene represented in this entry.

Polymorphism. Position 161 is associated with platelet-specific alloantigen Siba. Siba(-) has Thr-161 and Siba(+) has Met-161. Siba is involved in neonatal alloimmune thrombocytopenia (NATP). Polymorphisms arise from a variable number of tandem 13-amino acid repeats of S-E-P-A-P-S-P-T-T-P-E-P-T in the mucin-like macroglycopeptide (Pro/Thr-rich) domain. Allele D contains one repeat starting at position 415, allele C contains two repeats, allele B (shown here) contains three repeats and allele A contains four repeats. Allele B is associated with susceptibility to nonarteritic anterior ischemic optic neuropathy.

Miscellaneous. Platelet activation apparently involves disruption of the macromolecular complex of GP-Ib with the platelet glycoprotein IX (GP-IX) and dissociation of GP-Ib from the actin-binding protein.

RefSeq proteins (1): NP_000164* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000372	LRRNT	Domain
IPR000483	Cys-rich_flank_reg_C	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily

Pfam: PF01462, PF13855

UniProt features (124 total): glycosylation site 44, strand 17, sequence variant 13, helix 10, repeat 7, turn 6, modified residue 5, disulfide bond 5, compositionally biased region 3, mutagenesis site 3, chain 2, domain 2, topological domain 2, signal peptide 1, region of interest 1, site 1, transmembrane region 1, sequence conflict 1

Structure

Experimental structures (PDB)

22 structures.

PDB	Method	Resolution (Å)
4CH2	X-RAY DIFFRACTION	1.6
1P9A	X-RAY DIFFRACTION	1.7
4CH8	X-RAY DIFFRACTION	1.75
1M0Z	X-RAY DIFFRACTION	1.85
3P72	X-RAY DIFFRACTION	1.9
4C2A	X-RAY DIFFRACTION	2.08
8WE2	X-RAY DIFFRACTION	2.11
1OOK	X-RAY DIFFRACTION	2.3
2BP3	X-RAY DIFFRACTION	2.32
4YR6	X-RAY DIFFRACTION	2.38
8WF6	X-RAY DIFFRACTION	2.47
1P8V	X-RAY DIFFRACTION	2.6
1SQ0	X-RAY DIFFRACTION	2.6
1GWB	X-RAY DIFFRACTION	2.8
1QYY	X-RAY DIFFRACTION	2.8
4C2B	X-RAY DIFFRACTION	2.8
1U0N	X-RAY DIFFRACTION	2.95
1M10	X-RAY DIFFRACTION	3.1
4MGX	X-RAY DIFFRACTION	3.16
3PMH	X-RAY DIFFRACTION	3.2
6XFQ	X-RAY DIFFRACTION	3.3
8WFS	ELECTRON MICROSCOPY	3.36

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P07359-F1	64.65	0.38

Antibody-complex structures (SAbDab): 1 — 4YR6

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 506–507 (cleavage; by adam17)

Post-translational modifications (5): 292, 294, 295, 629, 632

Disulfide bonds (5): 20–33, 225–264, 227–280, 526, 527

Glycosylation sites (44): 37, 175, 308, 316, 320, 321, 328, 331, 340, 341, 345, 353, 354, 360, 364, 369, 371, 373, 379, 380 …

Mutagenesis-validated functional residues (3):

Position	Phenotype
249	no change.
249	decreased binding to vwf.
249	increased binding to vwf.

Function

Pathways and Gene Ontology

Reactome pathways

11 pathways

ID	Pathway
R-HSA-430116	GP1b-IX-V activation signalling
R-HSA-75892	Platelet Adhesion to exposed collagen
R-HSA-76009	Platelet Aggregation (Plug Formation)
R-HSA-8936459	RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
R-HSA-9673221	Defective F9 activation
R-HSA-9769739	Regulation of clotting cascade
R-HSA-9769743	Amplification and propagation of coagulation cascade
R-HSA-9845620	Enhanced binding of GP1BA variant to VWF multimer:collagen
R-HSA-9846298	Defective binding of VWF variant to GPIb:IX:V
R-HSA-9935598	FXIIa, PKa-dependent activation of coagulation pathway
R-HSA-140837

MSigDB gene sets: 286 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_PROTEIN_ACTIVATION_CASCADE, GOBP_REGULATION_OF_WOUND_HEALING, GOBP_MYELOID_CELL_DEVELOPMENT, GOBP_REGULATION_OF_COAGULATION, REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION, REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION, GOBP_PLATELET_ACTIVATION, GOCC_CELL_SURFACE, KONG_E2F3_TARGETS, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_NEGATIVE_REGULATION_OF_COAGULATION, GOBP_WOUND_HEALING, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS

GO Biological Process (13): cell morphogenesis (GO:0000902), cell adhesion (GO:0007155), cell surface receptor signaling pathway (GO:0007166), blood coagulation (GO:0007596), blood coagulation, intrinsic pathway (GO:0007597), positive regulation of platelet activation (GO:0010572), platelet activation (GO:0030168), regulation of blood coagulation (GO:0030193), megakaryocyte development (GO:0035855), fibrinolysis (GO:0042730), release of sequestered calcium ion into cytosol (GO:0051209), hemostasis (GO:0007599), thrombin-activated receptor signaling pathway (GO:0070493)

GO Molecular Function (3): thrombin-activated receptor activity (GO:0015057), signaling receptor activity (GO:0038023), protein binding (GO:0005515)

GO Cellular Component (6): plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), membrane (GO:0016020), extracellular exosome (GO:0070062), glycoprotein Ib-IX-V complex (GO:1990779)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Platelet activation, signaling and aggregation	2
Coagulation pathway	2
Defects of platelet adhesion to exposed collagen	2
Hemostasis	1
Transcriptional regulation by RUNX1	1
Defective factor IX causes hemophilia B	1
Regulation of clotting cascade	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
blood coagulation	2
cellular anatomical structure	2
anatomical structure morphogenesis	1
cellular process	1
signal transduction	1
hemostasis	1
wound healing	1
coagulation	1
protein activation cascade	1
blood coagulation, fibrin clot formation	1
regulation of platelet activation	1
platelet activation	1
positive regulation of cell activation	1
cell activation	1
regulation of response to external stimulus	1
regulation of coagulation	1
regulation of wound healing	1
regulation of hemostasis	1
megakaryocyte differentiation	1
myeloid cell development	1
negative regulation of blood coagulation	1
intercellular transport	1
calcium ion transmembrane import into cytosol	1
regulation of body fluid levels	1
G protein-coupled receptor signaling pathway	1
proteinase-activated receptor activity	1
thrombin-activated receptor signaling pathway	1
molecular transducer activity	1
binding	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1
extracellular vesicle	1
glycoprotein complex	1
plasma membrane signaling receptor complex	1

Protein interactions and networks

STRING

1640 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GP1BA	VWF	P04275	999
GP1BA	GP9	P14770	999
GP1BA	GP1BB	P13224	999
GP1BA	SELP	P16109	998
GP1BA	FLNA	P21333	987
GP1BA	ITGAM	P11215	982
GP1BA	ITGB2	P05107	977
GP1BA	ITGA2B	P08514	948
GP1BA	ADAMTS13	Q76LX8	931
GP1BA	GP6	Q9HCN6	917
GP1BA	FLNB	O75369	906
GP1BA	SELPLG	Q14242	900
GP1BA	ITGB3	P05106	862
GP1BA	FN1	P02751	841
GP1BA	FLNC	Q14315	832

IntAct

24 interactions, top by confidence:

A	B	Type	Score
GP9	GP1BA	psi-mi:“MI:0914”(association)	0.790
GP1BA	GP9	psi-mi:“MI:2364”(proximity)	0.790
GP1BA	GP1BB	psi-mi:“MI:0407”(direct interaction)	0.700
GP1BA	GP1BB	psi-mi:“MI:0915”(physical association)	0.700
GP1BA	VWF	psi-mi:“MI:0407”(direct interaction)	0.620
VWF	GP1BA	psi-mi:“MI:0407”(direct interaction)	0.620
GP1BA	YWHAZ	psi-mi:“MI:0914”(association)	0.530
GP1BA	NECTIN2	psi-mi:“MI:0915”(physical association)	0.400
GP1BA	S	psi-mi:“MI:0915”(physical association)	0.400
GP1BA	F2	psi-mi:“MI:0915”(physical association)	0.400
ECE1	GP1BA	psi-mi:“MI:0915”(physical association)	0.370
GP1BA	YWHAB	psi-mi:“MI:0914”(association)	0.350
GP1BA	YWHAE	psi-mi:“MI:0914”(association)	0.350
GP1BA	YWHAH	psi-mi:“MI:0914”(association)	0.350
GP1BA	YWHAG	psi-mi:“MI:0914”(association)	0.350
YWHAQ	GP1BA	psi-mi:“MI:0914”(association)	0.350
FLNA	GP1BA	psi-mi:“MI:2364”(proximity)	0.270
F12	GP1BA	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (39): FLNA (Co-localization), F12 (Co-localization), GP9 (Affinity Capture-Western), GP1BB (Affinity Capture-Western), YWHAZ (Affinity Capture-Western), VWF (Reconstituted Complex), VWF (Far Western), GP1BA (Affinity Capture-MS), GP1BA (Affinity Capture-Western), YWHAZ (Affinity Capture-Western), PIK3R1 (Affinity Capture-Western), CALM1 (Affinity Capture-Western), SRC (Affinity Capture-Western), LYN (Affinity Capture-Western), PIK3R1 (Affinity Capture-Western)

ESM2 similar proteins: A0A1B0GUW6, A0A2R8Y7Y5, A4FU49, A6QLF8, A6QQS3, I3L273, J3KML8, O00592, O35930, P06484, P07359, P0C671, P34910, Q1ECS6, Q3MIW9, Q3TNW5, Q3V3Q4, Q4R729, Q52S86, Q5SWP3, Q5VYM1, Q62170, Q64519, Q6AZ54, Q6MG22, Q6UXF1, Q7TSG5, Q7Z434, Q7Z7G0, Q810T2, Q8BHE4, Q8JZQ0, Q8K4E0, Q8N1P7, Q8N3K9, Q8N5Q1, Q8TCU4, Q8VD58, Q95JY5, Q96KW9

Diamond homologs: A3KNN3, A6H789, A6H793, A6NJW4, A8WHP9, E7FE13, F1MLX5, G5EFX6, O02678, O02833, O35367, O46378, O46379, O46542, O60938, O62702, O75093, O75094, O88279, O88280, O94813, P07359, P07585, P21793, P24014, P28654, P28675, P35858, P35859, P51884, P51885, P51886, P51888, P51890, P58874, P59034, P59035, P70186, P70389, P83286

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
GATA1	“up-regulates quantity by expression”	GP1BA	“transcriptional regulation”
RUNX1	“up-regulates quantity by expression”	GP1BA	“transcriptional regulation”
GP1BA	“form complex”	“GPIb-IX-V complex”	binding
ADAM17	“down-regulates activity”	GP1BA	cleavage

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 15 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	6	326.3×	4e-13
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	6	287.9×	5e-13
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	6	287.9×	5e-13
Activation of BH3-only proteins	6	212.8×	3e-12
RHO GTPases activate PKNs	6	135.9×	5e-11
Intrinsic Pathway for Apoptosis	6	125.5×	7e-11
SARS-CoV-1-host interactions	6	75.3×	2e-09
Apoptosis	6	72.0×	2e-09

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	5	130.8×	2e-08
intracellular protein localization	6	44.9×	1e-07

Disease & clinical

Clinical variants and AI predictions

ClinVar

337 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	20
Likely pathogenic	68
Uncertain significance	161
Likely benign	54
Benign	13

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1677212	NM_000173.7(GP1BA):c.241T>C (p.Cys81Arg)	Pathogenic
1677260	NM_000173.7(GP1BA):c.1326_1334del (p.Glu442_Pro445delinsAsp)	Pathogenic
1677261	NM_000173.7(GP1BA):c.58T>G (p.Cys20Gly)	Pathogenic
1677262	NM_000173.7(GP1BA):c.793G>T (p.Asp265Tyr)	Pathogenic
1677263	NM_000173.7(GP1BA):c.746G>A (p.Gly249Asp)	Pathogenic
1679419	NM_000173.7(GP1BA):c.499G>T (p.Glu167Ter)	Pathogenic
1684364	NM_000173.7(GP1BA):c.737G>T (p.Trp246Leu)	Pathogenic
1691251	NM_000173.7(GP1BA):c.1480del (p.Thr494fs)	Pathogenic
1691252	NM_000173.7(GP1BA):c.674G>C (p.Cys225Ser)	Pathogenic
1703858	NM_000173.7(GP1BA):c.1846_1852del (p.Asn616fs)	Pathogenic
2137887	NM_000173.7(GP1BA):c.1454dup (p.Ser486fs)	Pathogenic
2572131	NM_000173.7(GP1BA):c.1408del (p.Ser470fs)	Pathogenic
4156	NM_000173.7(GP1BA):c.515C>T (p.Ala172Val)	Pathogenic
4157	NM_000173.7(GP1BA):c.1620G>A (p.Trp540Ter)	Pathogenic
435347	NM_000173.7(GP1BA):c.673T>A (p.Cys225Ser)	Pathogenic
4539007	NM_000173.7(GP1BA):c.1562_1563del (p.Leu521fs)	Pathogenic
627001	NM_000173.7(GP1BA):c.148_149del (p.Thr50fs)	Pathogenic
872580	NM_000173.7(GP1BA):c.986G>A (p.Trp329Ter)	Pathogenic
872581	NM_000173.7(GP1BA):c.1601_1602del (p.Tyr534fs)	Pathogenic
988865	NM_000173.7(GP1BA):c.1274_1275del (p.Glu425fs)	Pathogenic
1013123	NM_000173.7(GP1BA):c.1792_1795del (p.Leu598fs)	Likely pathogenic
1031446	NM_000173.7(GP1BA):c.673T>C (p.Cys225Arg)	Likely pathogenic
1324497	NM_000173.7(GP1BA):c.1263_1264del (p.Thr422fs)	Likely pathogenic
1676741	NM_000173.7(GP1BA):c.169A>G (p.Asn57Asp)	Likely pathogenic
1677265	NM_000173.7(GP1BA):c.247C>T (p.Leu83Phe)	Likely pathogenic
1684365	NM_000173.7(GP1BA):c.434T>C (p.Leu145Pro)	Likely pathogenic
1684366	NM_000173.7(GP1BA):c.1951dup (p.Ser651fs)	Likely pathogenic
1684370	NM_000173.7(GP1BA):c.1283C>G (p.Ser428Ter)	Likely pathogenic
1684403	NM_000173.7(GP1BA):c.98G>A (p.Cys33Tyr)	Likely pathogenic
2440587	NM_000173.7(GP1BA):c.1480dup (p.Thr494fs)	Likely pathogenic

SpliceAI

187 predictions. Top by Δscore:

Variant	Effect	Δscore
17:4932362:GCCT:G	donor_gain	1.0000
17:4932624:T:A	acceptor_gain	1.0000
17:4932347:G:GT	donor_gain	0.9900
17:4932366:G:GG	donor_gain	0.9900
17:4932593:CCACA:C	acceptor_loss	0.9700
17:4932596:C:G	acceptor_loss	0.9700
17:4932597:A:AC	acceptor_loss	0.9700
17:4932598:G:GC	acceptor_loss	0.9700
17:4932664:TG:T	acceptor_gain	0.9700
17:4932361:TGCCT:T	donor_gain	0.9600
17:4932362:GCCTG:G	donor_gain	0.9600
17:4932364:CT:C	donor_gain	0.9600
17:4932367:T:G	donor_loss	0.9600
17:4932665:G:GT	acceptor_gain	0.9600
17:4932363:CCT:C	donor_gain	0.9500
17:4932368:AAG:A	donor_loss	0.9500
17:4932662:TGTG:T	acceptor_gain	0.9500
17:4932351:T:TA	donor_gain	0.9200
17:4932633:T:A	acceptor_gain	0.9200
17:4932630:T:TA	acceptor_gain	0.9100
17:4932597:A:AG	acceptor_gain	0.8900
17:4932598:G:GG	acceptor_gain	0.8900
17:4932352:C:A	donor_gain	0.8800
17:4932621:T:A	acceptor_gain	0.8500
17:4932370:G:C	donor_loss	0.8400
17:4932598:GGTC:G	acceptor_gain	0.8400
17:4932661:CTGTG:C	acceptor_gain	0.8300
17:4932353:T:TG	donor_gain	0.7900
17:4932373:GGG:G	donor_gain	0.7600
17:4932374:GGG:G	donor_gain	0.7600

AlphaMissense

4165 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:4933273:G:C	W223C	0.998
17:4933273:G:T	W223C	0.998
17:4933271:T:A	W223R	0.995
17:4933271:T:C	W223R	0.995
17:4933394:T:A	C264S	0.995
17:4933395:G:C	C264S	0.995
17:4933309:G:C	W235C	0.994
17:4933309:G:T	W235C	0.994
17:4933277:T:A	C225S	0.993
17:4933278:G:C	C225S	0.993
17:4933110:T:C	L169P	0.992
17:4933131:T:C	L176S	0.992
17:4933198:C:A	N198K	0.992
17:4933198:C:G	N198K	0.992
17:4933253:T:C	F217L	0.992
17:4933255:T:A	F217L	0.992
17:4933255:T:G	F217L	0.992
17:4933394:T:C	C264R	0.992
17:4932982:C:A	N126K	0.990
17:4932982:C:G	N126K	0.990
17:4933278:G:A	C225Y	0.990
17:4933054:T:A	N150K	0.989
17:4933054:T:G	N150K	0.989
17:4933188:T:A	L195H	0.989
17:4933311:T:C	L236P	0.989
17:4933277:T:C	C225R	0.988
17:4933126:C:A	N174K	0.987
17:4933126:C:G	N174K	0.987
17:4933182:T:C	L193P	0.987
17:4933196:A:T	N198Y	0.987

dbSNP variants (sampled 300 via entrez): RS1000776968 (17:4931578 C>T), RS1000783070 (17:4933519 G>C), RS1000836753 (17:4933712 A>G), RS1001693764 (17:4934761 T>G), RS1001788424 (17:4934801 C>A,T), RS1002715460 (17:4930937 A>G,T), RS1004006658 (17:4931977 C>T), RS1004130544 (17:4932179 G>A), RS1004339214 (17:4930929 TTAGG>T), RS1005076777 (17:4932055 C>T), RS1005736598 (17:4934703 A>G), RS1006488234 (17:4935032 T>C), RS1006973813 (17:4935337 G>A), RS1007152155 (17:4932475 T>A,C), RS1007482772 (17:4934066 T>G)

Disease associations

OMIM: gene MIM:606672 | disease phenotypes: MIM:231200, MIM:177820, MIM:153670, MIM:258660

GenCC curated gene-disease

Disease	Classification	Inheritance
Bernard-Soulier syndrome	Definitive	Autosomal recessive
platelet-type von Willebrand disease	Strong	Autosomal dominant
Bernard-Soulier syndrome, type A2, autosomal dominant	Strong	Autosomal dominant
autosomal dominant macrothrombocytopenia	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (2)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
Bernard-Soulier syndrome	Definitive	AR
platelet-type von Willebrand disease	Definitive	AD

Mondo (7): Bernard-Soulier syndrome (MONDO:0009276), platelet-type von Willebrand disease (MONDO:0008332), Bernard-Soulier syndrome, type A2, autosomal dominant (MONDO:0007930), nonarteritic anterior ischemic optic neuropathy, susceptibility to (MONDO:0009789), CIC-rearranged sarcoma (MONDO:0956989), thrombocytopenia (MONDO:0002049), autosomal dominant macrothrombocytopenia (MONDO:0015372)

Orphanet (2): Bernard-Soulier syndrome (Orphanet:274), Pseudo-von Willebrand disease (Orphanet:52530)

HPO phenotypes

50 total (30 of 50 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000132	Menorrhagia
HP:0000225	Gingival bleeding
HP:0000421	Epistaxis
HP:0000618	Blindness
HP:0000707	Abnormality of the nervous system
HP:0000790	Hematuria
HP:0000967	Petechiae
HP:0000978	Bruising susceptibility
HP:0000979	Purpura
HP:0001250	Seizure
HP:0001263	Global developmental delay
HP:0001744	Splenomegaly
HP:0001873	Thrombocytopenia
HP:0001878	Hemolytic anemia
HP:0001892	Abnormal bleeding
HP:0001902	Giant platelets
HP:0002076	Migraine
HP:0002099	Asthma
HP:0002138	Subarachnoid hemorrhage
HP:0002170	Intracranial hemorrhage
HP:0002239	Gastrointestinal hemorrhage
HP:0002248	Hematemesis
HP:0002249	Melena
HP:0003010	Prolonged bleeding time
HP:0003577	Congenital onset
HP:0004406	Spontaneous, recurrent epistaxis
HP:0004446	Stomatocytosis
HP:0004809	Neonatal alloimmune thrombocytopenia

GWAS associations

17 associations (top):

Study	Trait	p-value
GCST000580_7	Platelet count	2.000000e-12
GCST001337_48	Platelet count	3.000000e-11
GCST004599_113	Mean platelet volume	8.000000e-10
GCST004603_172	Platelet count	2.000000e-15
GCST004616_73	Platelet distribution width	1.000000e-12
GCST004616_74	Platelet distribution width	1.000000e-21
GCST005991_41	Platelet count	5.000000e-60
GCST006585_257	Blood protein levels	2.000000e-14
GCST90002395_238	Mean platelet volume	9.000000e-30
GCST90002395_266	Mean platelet volume	6.000000e-24
GCST90002395_267	Mean platelet volume	2.000000e-19
GCST90002400_201	Plateletcrit	2.000000e-18
GCST90002401_576	Platelet distribution width	2.000000e-35
GCST90002401_578	Platelet distribution width	3.000000e-41
GCST90002402_433	Platelet count	1.000000e-13
GCST90002402_435	Platelet count	2.000000e-32
GCST90013442_27	Keratoconus	2.000000e-14

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004309	platelet count
EFO:0007984	platelet component distribution width
EFO:0007985	platelet crit

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D001606	Bernard-Soulier Syndrome	C15.378.100.100.080; C15.378.140.120; C15.378.463.080; C16.320.099.080
D013921	Thrombocytopenia	C15.378.140.855; C15.378.243.937
C536458	Von Willebrand disease, platelet type (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4630891 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs6065	Efficacy	3	aspirin

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs6065	GP1BA	3	3.75	1	aspirin
rs2243093	GP1BA		0.00	0

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aspirin	increases response to substance, decreases response to substance, affects response to substance	3
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid	decreases reaction, increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
phosphatidylinositol 3,4,5-triphosphate	affects binding, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	decreases reaction, increases expression	1
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	decreases reaction, increases expression	1
U 0126	decreases reaction, increases expression	1
pyrazolanthrone	increases expression, increases reaction	1
jinfukang	increases expression	1
prothioconazole	decreases expression	1
10-(4’-(N-diethylamino)butyl)-2-chlorophenoxazine	decreases reaction, increases expression	1
Acetylcysteine	decreases reaction, increases expression	1
Amphotericin B	increases expression	1
Atrazine	increases expression	1
Vehicle Emissions	increases secretion	1
Benzene	decreases expression	1
Cholesterol	increases expression	1
Lipopolysaccharides	increases expression, affects response to substance, affects cotreatment	1
Tetradecanoylphorbol Acetate	decreases reaction, increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Urethane	increases expression	1
Antirheumatic Agents	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B8GX	Abcam HCT 116 GP1BA KO	Cancer cell line	Male
CVCL_B8WD	Abcam MCF-7 GP1BA KO	Cancer cell line	Female
CVCL_B9J6	Abcam A-549 GP1BA KO	Cancer cell line	Male

Clinical trials (associated diseases)

243 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00039858	PHASE4	COMPLETED	Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
NCT00239733	PHASE4	TERMINATED	Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
NCT00907478	PHASE4	COMPLETED	Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
NCT01727401	PHASE4	TERMINATED	Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia
NCT02032134	PHASE4	TERMINATED	Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia
NCT02267993	PHASE4	COMPLETED	Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients
NCT03633019	PHASE4	UNKNOWN	High-dose Use of rhTPO in CIT Patients
NCT03688191	PHASE4	UNKNOWN	Study of Sirolimus in CTD-TP in China
NCT04906083	PHASE4	UNKNOWN	Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia
NCT05217719	PHASE4	UNKNOWN	Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients
NCT05255003	PHASE4	RECRUITING	STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
NCT05382013	PHASE4	UNKNOWN	Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment
NCT05944458	PHASE4	COMPLETED	Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients
NCT06562738	PHASE4	RECRUITING	Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia
NCT00037791	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00039910	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00073580	PHASE3	COMPLETED	Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
NCT00102323	PHASE3	COMPLETED	AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
NCT00102336	PHASE3	COMPLETED	AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
NCT00116688	PHASE3	COMPLETED	Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00128713	PHASE3	COMPLETED	Optimal Platelet Dose Strategy for Management of Thrombocytopenia
NCT00151866	PHASE3	COMPLETED	Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma
NCT00261924	PHASE3	COMPLETED	Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days
NCT00415532	PHASE3	COMPLETED	Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
NCT00420914	PHASE3	TERMINATED	Strategies for Transfusion of Platelets (SToP)
NCT00501345	PHASE3	TERMINATED	Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
NCT00508820	PHASE3	COMPLETED	An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
NCT00678587	PHASE3	TERMINATED	Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
NCT01438840	PHASE3	COMPLETED	Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)
NCT01444417	PHASE3	COMPLETED	Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT01805648	PHASE3	UNKNOWN	Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP
NCT02244658	PHASE3	UNKNOWN	Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
NCT02389621	PHASE3	COMPLETED	Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
NCT02444728	PHASE3	TERMINATED	Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
NCT02487563	PHASE3	COMPLETED	Prospective Study of Patients With Thrombocytopenia Following HSCT
NCT02578901	PHASE3	COMPLETED	American Trial Using Tranexamic Acid in Thrombocytopenia
NCT03326843	PHASE3	TERMINATED	Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure
NCT03515096	PHASE3	COMPLETED	Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT
NCT05563064	PHASE3	UNKNOWN	Effect of Herbal Formulation on Thrombocytes Count
NCT07442513	PHASE3	RECRUITING	Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT